Voyager Therapeutics Inc Receives a Buy from BTIG


In a report released yesterday, Dane Leone from BTIG maintained a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR), with a price target of $32. The company’s shares closed yesterday at $22.50.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 20.5% and a 71.5% success rate. Leone covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Blueprint Medicines, and G1 Therapeutics Inc.

Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $34.71, representing a 54.3% upside.

In a report issued on May 29, Canaccord Genuity also maintained a Buy rating on the stock with a $35 price target.

See today’s analyst top recommended stocks >>

Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.93 million. In comparison, last year the company had a GAAP net loss of $16.65 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts